CINECA IRIS Institutional Research Information System

LATROFA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 14.147
NA - Nord America 11.191
AS - Asia 4.118
SA - Sud America 903
AF - Africa 255
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 5
Totale 30.626
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 10.856
US - Stati Uniti d'America 8.640
CA - Canada 2.483
SG - Singapore 1.284
CN - Cina 1.126
HK - Hong Kong 815
BR - Brasile 728
SE - Svezia 701
DE - Germania 472
NL - Olanda 405
VN - Vietnam 313
BG - Bulgaria 267
FR - Francia 246
GB - Regno Unito 244
AT - Austria 183
TR - Turchia 158
UA - Ucraina 145
RU - Federazione Russa 138
FI - Finlandia 134
IN - India 97
CI - Costa d'Avorio 94
CH - Svizzera 61
JP - Giappone 58
SN - Senegal 57
AR - Argentina 50
KR - Corea 50
PL - Polonia 46
ES - Italia 43
MX - Messico 41
ZA - Sudafrica 35
BE - Belgio 31
EC - Ecuador 27
PY - Paraguay 27
BD - Bangladesh 26
IQ - Iraq 26
RO - Romania 23
LV - Lettonia 21
CO - Colombia 20
ID - Indonesia 20
IE - Irlanda 19
SA - Arabia Saudita 16
VE - Venezuela 15
EG - Egitto 14
GR - Grecia 14
UZ - Uzbekistan 14
CL - Cile 13
JO - Giordania 13
MA - Marocco 13
CZ - Repubblica Ceca 12
DK - Danimarca 12
PK - Pakistan 12
PE - Perù 11
ZM - Zambia 11
EE - Estonia 10
SM - San Marino 10
IL - Israele 9
AE - Emirati Arabi Uniti 8
HU - Ungheria 8
KE - Kenya 8
KZ - Kazakistan 8
TW - Taiwan 8
AL - Albania 7
AU - Australia 7
HR - Croazia 7
IR - Iran 7
PH - Filippine 7
TH - Thailandia 7
UY - Uruguay 7
AZ - Azerbaigian 6
MY - Malesia 6
RS - Serbia 6
JM - Giamaica 5
MT - Malta 5
PT - Portogallo 5
TN - Tunisia 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
LT - Lituania 4
CR - Costa Rica 3
ET - Etiopia 3
GE - Georgia 3
GT - Guatemala 3
HN - Honduras 3
LA - Repubblica Popolare Democratica del Laos 3
LY - Libia 3
NG - Nigeria 3
NP - Nepal 3
OM - Oman 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BO - Bolivia 2
BW - Botswana 2
EU - Europa 2
KG - Kirghizistan 2
LU - Lussemburgo 2
NO - Norvegia 2
PA - Panama 2
PR - Porto Rico 2
QA - Qatar 2
SI - Slovenia 2
Totale 30.602
Salva come PNG Salva come JPEG
Città #
Montreal 2.326
Ashburn 950
Milan 910
Hong Kong 807
Dallas 804
Fairfield 767
Woodbridge 746
Singapore 652
Rome 639
Ann Arbor 582
Santa Clara 536
Houston 500
Chandler 442
Seattle 327
Beijing 289
Florence 274
Naples 263
Sofia 262
Shanghai 258
Wilmington 256
New York 243
Cambridge 239
Serra 207
Bologna 155
Vienna 155
Boardman 144
Pisa 137
Bari 129
Los Angeles 129
Princeton 121
Ottawa 119
Palermo 116
Turin 109
Lawrence 106
Munich 104
Medford 95
Abidjan 94
Ho Chi Minh City 94
Catania 89
Brescia 78
Hefei 78
Genoa 76
Nanjing 67
Izmir 66
London 66
Des Moines 62
São Paulo 62
Dakar 57
Padova 57
Dong Ket 56
Bremen 53
Redondo Beach 53
Vicopisano 53
Hanoi 52
Lucca 50
Livorno 49
Cagliari 47
Seoul 47
Verona 46
Frankfurt am Main 45
Dearborn 44
Istanbul 43
San Diego 42
Tokyo 42
Buffalo 37
Jacksonville 37
Turku 37
Redwood City 36
Bergamo 35
Pescara 35
Paris 34
Helsinki 33
Modena 32
Marseille 31
Ogden 31
Lancaster 30
Messina 29
Guangzhou 28
Perugia 28
Napoli 27
Boulder 26
Nanchang 26
Rio de Janeiro 26
San Jose 24
Ancona 22
Brussels 22
Caserta 22
Chicago 22
Düsseldorf 22
Rende 22
Salerno 22
Fuzhou 21
Monza 21
Reggio Emilia 21
Taranto 21
Toronto 21
Venice 21
Reggio Calabria 20
Torino 20
Brooklyn 19
Totale 17.527
Salva come PNG Salva come JPEG
Nome #
Tiroidite cronica autoimmune 10.072
Ipotiroidismo subclinico 3.302
Gozzo diffuso tossico (morbo di Flajani-Basedow-Graves) e tiroidite cronica autoimmune, Inquadramento nosologico e terapia medica 236
Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy 225
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 221
Le malattie autoimmuni della tiroide 209
Role of the underlying thyroid disease on the phenotype of graves' orbitopathy in a tertiary referral center 204
Effects Of Long-term Tamoxifen Therapy On The Course Of Chronic Autoimmune Thyroiditis 202
Iodine contributes to thyroid autoimmunity in humans by unmasking a cryptic epitope on thyroglobulin. 200
Diagnosi differenziale dell’oftalmopatia basedowiana 199
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade 194
Causes and laboratory investigations of thyrotoxicosis 191
Subacute thyroiditis after Sars-COV-2 infection 186
Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts 185
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 184
The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis 181
Effect of thyroglobulin autoantibodies on the metabolic clearance of serum thyroglobulin 180
Thyroglobulin Autoantibodies arise before Thyroperoxidase Autoantibodies in Juvenile Autoimmune Thyroiditis 179
Significance of low levels of thyroglobulin autoantibodies associated with undetectable thyroglobulin after thyroidectomy for differentiated thyroid carcinoma 178
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 178
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 176
Outcome of Graves' Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial 176
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial 176
Circulating thyroglobulin transcytosed by thyroid cells is complexed with secretory components of its endocytic receptor megalin 175
Thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: comparison of different assays and evaluation of causes of discrepancies. 174
Spontaneous improvement of untreated mild graves' ophthalmopathy: Rundle's curve revisited. 174
Graves' Disease Induced by Immune Checkpoint Inhibitors: A case report and Review of the literature 173
Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? insights from a case series 173
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 170
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 169
Diagnostic accuracy of a new fluoroenzyme immunoassay for the detection of TSH receptor autoantibodies in Graves' disease 169
Serum antibodies against megalin (gp330) in patients with autoimmune thyroiditis 168
The large majority of 1520 patients with indeterminate thyroid nodule at cytology have a favorable outcome, and a clinical risk score has a high negative predictive value for a more cumbersome cancer disease. 168
Compared with classic Hashimoto’s thyroiditis, chronic autoimmune serum‑negative thyroiditis requires a lower substitution dose of l‑thyroxine to correct hypothyroidism 167
Pathogenetic and clinical aspects of autoimmune thyroiditis 165
Clinical features of thyroid autoimmunity are associated with thyroiditis on histology and are not predictive of malignancy in 570 patients with indeterminate nodules on cytology who had a thyroidectomy 165
VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY 165
Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy 165
Patients with indeterminate thyroid nodules at cytology and cancer at histology have a more favourable outcome with respect to patients with suspicious or malignant cytology 165
Optic neuropathy in 2 thyroidectomized patients with moderate to severe Graves’ ophthalmopathy following L-thyroxine withdrawal prior to radioiodine treatment for thyroid carcinoma 163
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 163
Thyroid imaging in the management of anti-PD1/PD-L1 induced thyrotoxicosis 163
Human monoclonal thyroglobulin autoantibodies: epitopes and immunoglobulin genes. 162
Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine 161
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases 160
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 159
Effect of thyroglobulin autoantibodies on the clearance of serum thyroglobulin in humans 159
Cytological and Ultrasound Features of Thyroid Nodules Correlate with Histotypes and Variants of Thyroid Carcinoma 158
Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. 155
Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question 155
IgM thyroglobulin autoantibodies are detectable in serum of patients with subacute thyroiditis 155
Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology 152
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 151
Outcome of Graves’ Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial 148
Thyroid volume and severity of graves' orbitopathy 147
Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy 147
The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors 145
Intracellular retention of thyroglobulin in the absence of the low-density lipoprotein receptor-associated protein (RAP) is likely due to premature binding to megalin in the biosynthetic pathway 144
Activating Antibodies to the Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism 143
Pathways to democratized healthcare: Envisioning human-centered AI-as-a-service for customized diagnosis and rehabilitation 141
Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study 138
Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis 136
In Graves' disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features 135
Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin. 134
Rehabilitative orbital decompression for Graves' orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients' satisfaction 133
Evaluation of the Level of Thyroglobulin Autoantibodies Interfering with Thyroglobulin Measurement in Patients with Differentiated Thyroid Carcinoma 131
Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player? 126
The detection of serum IgM to thyroglobulin in subacute thyroiditis suggests a protective role of IgM in thyroid autoimmunity 125
Diagnosi di laboratorio 124
Hypothyroidism Due to L-T4 Withdrawal Can Precipitate Optic Neuropathy in Patients with Moderate to Severe Graves' Ophthalmopathy: Report on Two Cases 124
The detection of serum IgMs to thyroglobulin in subacute thyroiditis suggests a protective role of IgMs in thyroid autoimmunity 123
null 121
Manifestaciones no oftalmológicas de la enfermedad de Graves 121
null 120
The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. 118
Subacute Thyroiditis during the SARS-CoV-2 Pandemic 118
Diffuse and Nodular Goiter 117
Thyroglobulin-thyroperoxidase autoantibodies are polyreactive, not bispecific: analysis using human monoclonal autoantibodies. 116
Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade 115
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 114
COVID-induced thyroid autoimmunity 113
Iodine, thyroid autoimmunity and cancer 112
Evidence that the thyrotropin receptor protease is membrane-associated and is not within lipid rafts 111
In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' orbitopathy 110
Thyroid stimulation does not require antibodies with identical epitopes but does involve recognition of a critical conformation at the N terminus of the thyrotropin receptor A-subunit. 110
Un caso di MEN2B con anomalie scheletriche multiple 109
Thyroglobulin Autoantibodies Switch to IgG1 and IgG3 Subclasses after 131I Treatment for Graves' Hyperthyroidism: Autoantibodies Subclasses Are Related to the Activity of Autoimmune Thyroid Disease 108
Gozzo 105
Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimus 105
Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. 104
Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis 102
null 100
null 100
Over hypothyroidism in a woman undergoing controlled ovarian hyperstimulation. 100
Clinical, biochemical features and functional outcome of patients with SARS-CoV-2-related subacute thyroiditis: a review 100
null 98
null 97
Altre terapie dell’oftalmopatia basedowiana 97
null 97
Frequency of the GPR7 Tyr135Phe allelic variant in lean and obese subjects. 97
Totale 27.934
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021870 0 0 0 0 0 0 97 148 148 137 133 207
2021/20221.926 61 103 61 152 297 239 83 97 194 154 108 377
2022/20233.354 250 306 246 219 250 269 146 261 506 192 425 284
2023/20246.548 364 317 315 311 383 462 377 354 204 2.651 399 411
2024/20257.083 390 344 368 525 615 635 536 519 768 709 637 1.037
2025/20264.608 535 806 900 1.152 654 533 28 0 0 0 0 0
Totale 30.993